SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- Portfolio Prep for Next Week: 'Don't Get Crazy'

MORE HEADLINES

» Markets | Economy | Companies

- Fed Audit Would Hurt Economic Prospects: Bernanke

PHARMA'S MARKET VIDEO

» More

Sebelius on Vaccines

24 Nov 2009

Discussing whether a new $487M investment from the government will help speed up the production of the most important vaccines, with Kathy Sebelius, Health & Human Services secretary and CNBC's Mike Huckman.

The New Formula for Faster Vaccines

24 Nov 2009

Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are faster, better and cheaper to make than egg-based methods, reports CNBC's Mike Huckman.

Novartis Opens 1st US Plant for Flu Vaccine

24 Nov 2009

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Pharma's Market

Text Size

Dec.31

11:55 AM ET

Wednesday, 31 Dec 2008

Lilly's New Year's Eve Party Pooper

Posted By:Mike Huckman

Topics:Stock Market | Corporate News | Pharmaceuticals

Sectors:Health Care | Pharmaceuticals

Companies:Eli Lilly and Company | Bristol-Myers Squibb Co

I thought I was going to be able to skip town for the Rose Bowl without needing to bang out another blog before my plane takes off. I was wrong.

This morning Eli Lilly announced what many analysts had been speculating for months was probably going to happen. The company's all-important bloodthinner Effient will be reviewed by an FDA Advisory Committee in early February.

These outside panels of experts are called on to examine drugs — especially if there are questions about safety — and are asked to make recommendations to the FDA about what to do. The agency usually, but not always, takes the advice.

In this case, there are concerns that Effient may do such a good job thinning the blood of certain patients that they bleed too much.

In the press release, J. Anthony Ware, M.D., Lilly vice president and cardiovascular/acute care platform leader for Effient, is quoted as saying, "We have full confidence in the data submitted to the FDA and the overall benefit-risk profile of prasugrel, and we look forward to this next step in potentially bringing an important new alternative to the oral antiplatelet market."
(Prasugrel is the generic, scientific name for Effient. )

The FDA has already twice delayed making a decision on whether to approve Effient, which it had put on a fast track for action. Lilly has repeatedly said the filing was ginormous -- that if you printed it out, the paper would stack nearly as high as the Empire State building.

Nevertheless, for months now Lilly [LLY Loading... () ] has been promoting Effient at scientific conferences and in medical publications, saying, "Coming Soon."

Bristol-Myers Squibb [BMY Loading... () ] and Sanofi-Aventis [SNY Loading... () ] are having the last laugh. They own the bloodthinner Plavix, which will get to continue to be the unchallenged 800-pound gorilla in that space for at least a little while longer.